Want to see HK:2172 full AI Analyst Report?
2172 Stock Chart & Stats
HK$11.30
HK$0.09(1.14%)
At close: 4:00 PM EST
HK$11.30
HK$0.09(1.14%)
Day’s Range― - ―
52-Week RangeHK$8.40 - HK$15.14
Previous CloseN/A
Volume491.15K
Average Volume (3M)2.57M
Market Cap
HK$5.08B
Enterprise ValueHK$5.21K
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$15.95M
Price to Earnings (P/E)22.7
Beta0.75
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.65%
Share Statistics
EPS (TTM)0.32
Shares Outstanding585,099,370
10 Day Avg. Volume2,683,063
30 Day Avg. Volume2,571,422
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)3.10
Price to Sales (P/S)7.24
P/FCF Ratio36.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.42
Revenue Forecast (FY)HK$874.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 72–78% indicate durable product-level pricing power typical of specialized medical devices. High gross margins support reinvestment in R&D, fund commercialization of new neurovascular therapies, and provide a structural buffer versus cost inflation, helping margins persist over time.
Strong Balance Sheet / Low LeverageVery low debt and markedly stronger equity since 2021 give the company lasting financial flexibility. This reduces refinancing risk, enables sustained investment in clinical trials and sales expansion, and improves resilience through reimbursement cycles or episodic product investments over the next several quarters.
Sustained Revenue GrowthA multi-year record of revenue expansion shows durable demand for its neuro-interventional devices. Continued positive top-line growth supports scale, recurring consumables sales, and deeper hospital adoption, which underpins long-term margin sustainability and the ability to fund product pipeline commercialization.
Bears Say
Inconsistent Cash-Flow ConversionWhen net income repeatedly fails to convert into operating cash, it weakens the firm's capacity to self-fund capex, clinical studies, and working capital needs. This structural inconsistency increases reliance on external financing and makes free-cash-flow durability and capital allocation less predictable.
Profitability Volatility / Recent Earnings DeclineA measurable decline in earnings in 2025 versus 2024 highlights execution or margin pressures that can persist. For device makers, profit volatility impairs long-term planning for R&D and commercialization, raises scrutiny on pricing and cost structure, and can limit consistent returns to stakeholders.
Historically Volatile CapitalizationPrior negative equity in 2021 points to past solvency strain and capitalization swings. Even with current low leverage, historical capital volatility signals governance or operational vulnerabilities that could re-emerge under stress, making long-term stability conditional on disciplined capital management.
MicroPort NeuroTech Limited News
2172 FAQ
What was MicroPort NeuroTech Limited’s price range in the past 12 months?
MicroPort NeuroTech Limited lowest stock price was HK$8.40 and its highest was HK$15.14 in the past 12 months.
What is MicroPort NeuroTech Limited’s market cap?
MicroPort NeuroTech Limited’s market cap is HK$5.08B.
When is MicroPort NeuroTech Limited’s upcoming earnings report date?
MicroPort NeuroTech Limited’s upcoming earnings report date is Aug 26, 2026 which is tomorrow.
How were MicroPort NeuroTech Limited’s earnings last quarter?
MicroPort NeuroTech Limited released its earnings results on Mar 25, 2026. The company reported HK$0.172 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MicroPort NeuroTech Limited overvalued?
According to Wall Street analysts MicroPort NeuroTech Limited’s price is currently Overvalued.
Does MicroPort NeuroTech Limited pay dividends?
MicroPort NeuroTech Limited pays a Quarterly dividend of HK$0.09 which represents an annual dividend yield of 1.65%. See more information on MicroPort NeuroTech Limited dividends here
What is MicroPort NeuroTech Limited’s EPS estimate?
MicroPort NeuroTech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort NeuroTech Limited have?
MicroPort NeuroTech Limited has 585,099,370 shares outstanding.
What happened to MicroPort NeuroTech Limited’s price movement after its last earnings report?
MicroPort NeuroTech Limited reported an EPS of HK$0.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.702%.
Which hedge fund is a major shareholder of MicroPort NeuroTech Limited?
Currently, no hedge funds are holding shares in HK:2172
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort NeuroTech Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.98%
12-Months-Change
Fundamentals
Return on Equity
1.65%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
MicroPort NeuroTech Limited
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―